1. Home
  2. GEN vs UTHR Comparison

GEN vs UTHR Comparison

Compare GEN & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gen Digital Inc.

GEN

Gen Digital Inc.

HOLD

Current Price

$20.71

Market Cap

14.8B

Sector

Technology

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$531.38

Market Cap

23.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GEN
UTHR
Founded
1982
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.8B
23.9B
IPO Year
1995
1999

Fundamental Metrics

Financial Performance
Metric
GEN
UTHR
Price
$20.71
$531.38
Analyst Decision
Buy
Buy
Analyst Count
8
14
Target Price
$33.63
$531.79
AVG Volume (30 Days)
5.0M
485.2K
Earning Date
05-05-2026
04-29-2026
Dividend Yield
2.43%
N/A
EPS Growth
7.29
13.07
EPS
0.74
27.86
Revenue
$6,676,000,000.00
$1,483,300,000.00
Revenue This Year
$27.40
$7.77
Revenue Next Year
$5.51
$11.11
P/E Ratio
$27.84
$19.04
Revenue Growth
N/A
2.38
52 Week Low
$20.46
$266.98
52 Week High
$32.22
$548.12

Technical Indicators

Market Signals
Indicator
GEN
UTHR
Relative Strength Index (RSI) 32.30 58.35
Support Level N/A $464.92
Resistance Level $27.24 $542.66
Average True Range (ATR) 0.58 14.71
MACD -0.07 2.68
Stochastic Oscillator 5.93 76.95

Price Performance

Historical Comparison
GEN
UTHR

About GEN Gen Digital Inc.

Gen is a cybersecurity pure-play that offers security, identity protection, and privacy solutions to individual consumers. The firm's cyber safety offerings, via brands such as Norton, Avast, and LifeLock, have long maintained their positions as some of the most recognizable consumer-focused security and identity-protection products.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: